Why Scienture Holdings, Inc.’s (SCNX) Stock Is Down 39.33%
As of Friday, October 24, Scienture Holdings, Inc.’s SCNX share price has dipped by 39.33%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Commentary & Analysis
Financial Summary
| Share Statistics | SCNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.6 | $179.6 | 9% |
|
| Shares Out (Mil) | 40.6 | 47.9 | 43% |
|
| Institutional Ownership | 24.8% | 78.6% | 12% |
|
| Float (Mil) | 32.8 | 40.1 | 38% |
|
| Beta | na | 1.22 | na |
|
| Avg Daily Volume (000s) | 280 | 205 | 50% |
|
| Price Change (52-week) |
(79.5%) | 41.0% | 7% |
|
| Growth | SCNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.7% | na |
|
| Net Income (5yr) | na | (1.0%) | na |
|
| EPS (5yr) | na | 15.5% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.5%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.090) | ($0.300) | ($0.060) | |
| Month Ago EPS | ($0.090) | ($0.300) | ($0.060) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.230) | ($0.720) | ($0.210) | |
| Year/Year Chg | 7.1% | (88.9%) | (106.3%) | |
| Financials | SCNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $192 | 1% |
|
| Net Income (TTM) (Mil) | ($42) | ($9) | 18% |
|
| EPS (TTM) | ($1.808) | ($0.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | $8 | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | ($3) | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $14 | 0% |
|
| Enterprise Value (Q1) (Mil) | $12 | $215 | 8% |
|
| Valuation | SCNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.23 | 1.22 | 4% |
|
| P/E | na | 36.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 2.0 | na |
|
| Ratios | SCNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 80.5% | 61.6% | 89% |
|
| Net Margin | na | (29.3%) | na |
|
| ROA | (44.8%) | (21.9%) | 13% |
|
| ROE | (56.6%) | (1.4%) | 14% |
|
| Liabilities to Assets | 17.2% | 33.3% | 11% |
|
| F-Score | 3 | 4 | 19% |
|
Scienture Holdings, Inc. did not pass any screens on 7/31/2026.
